Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Seikagaku Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Seikagaku Corporation - Product Pipeline Review - 2014', provides an overview of the Seikagaku Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Seikagaku Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Seikagaku Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Seikagaku Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Seikagaku Corporation's pipeline products Reasons to buy - Evaluate Seikagaku Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Seikagaku Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Seikagaku Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Seikagaku Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Seikagaku Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Seikagaku Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Seikagaku Corporation Snapshot 5 Seikagaku Corporation Overview 5 Key Information 5 Key Facts 5 Seikagaku Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 Seikagaku Corporation - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Seikagaku Corporation - Pipeline Products Glance 12 Seikagaku Corporation - Late Stage Pipeline Products 12 Pre-Registration Products/Combination Treatment Modalities 12 Phase III Products/Combination Treatment Modalities 13 Seikagaku Corporation - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Seikagaku Corporation - Drug Profiles 16 condoliase 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CF-101 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 hyaluronate sodium 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 SI-614 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 SI-613 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Seikagaku Corporation - Pipeline Analysis 25 Seikagaku Corporation - Pipeline Products by Target 25 Seikagaku Corporation - Pipeline Products by Route of Administration 26 Seikagaku Corporation - Pipeline Products by Molecule Type 27 Seikagaku Corporation - Pipeline Products by Mechanism of Action 28 Seikagaku Corporation - Recent Pipeline Updates 29 Seikagaku Corporation - Dormant Projects 34 Seikagaku Corporation - Locations And Subsidiaries 35 Head Office 35 Other Locations & Subsidiaries 35 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Seikagaku Corporation, Key Information 5 Seikagaku Corporation, Key Facts 5 Seikagaku Corporation - Pipeline by Indication, 2014 7 Seikagaku Corporation - Pipeline by Stage of Development, 2014 8 Seikagaku Corporation - Monotherapy Products in Pipeline, 2014 9 Seikagaku Corporation - Partnered Products in Pipeline, 2014 10 Seikagaku Corporation - Partnered Products/ Combination Treatment Modalities, 2014 11 Seikagaku Corporation - Pre-Registration, 2014 12 Seikagaku Corporation - Phase III, 2014 13 Seikagaku Corporation - Phase II, 2014 14 Seikagaku Corporation - Phase I, 2014 15 Seikagaku Corporation - Pipeline by Target, 2014 25 Seikagaku Corporation - Pipeline by Route of Administration, 2014 26 Seikagaku Corporation - Pipeline by Molecule Type, 2014 27 Seikagaku Corporation - Pipeline Products by Mechanism of Action, 2014 28 Seikagaku Corporation - Recent Pipeline Updates, 2014 29 Seikagaku Corporation - Dormant Developmental Projects,2014 34 Seikagaku Corporation, Other Locations 35 Seikagaku Corporation, Subsidiaries 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.